5th International Meeting on Aortic Diseases

New insights into an old problem

CHU Liège, APF

September 15-17
2016
Crowne Plaza Hotel
Liège, Belgium

www.chuliege-ima.be
am really honored to welcome you to the fifth edition of the International Meeting on Aortic Diseases that is organized from September 15 to 17, 2016 at the Crowne Plaza in Liège, Belgium.

This new edition is taking place in the historic center of Liège, during a famous Wallonian (local) festivity. The Crowne Plaza is at walking distance, but also from many hotels, and all facilities.

IMAD 2016 is focusing on new insights on basic research, as well as on the treatment of aortic valves, aneurysms, dissections (types A and B) and infection.

You are a vascular or a cardiac surgeon, you are a radiologist, a cardiologist, a geneticist, a biologist, an epidemiologist and/or any scientist, you are welcome in Liège. Please take the opportunity to share the experiences of the most renowned experts on aortic diseases, as well as to receive answers from them to any question you would have.

We are pleased to welcoming you in Liège to sharing with you another exciting conference on aortic diseases!

Natzi Sakalihasan

Under the patronage of:

- University of Liège
- Cardiovascular Surgery Department of CHU of Liège
- Province of Liège
- APF (Aneurysmal Pathology Foundation)
- Faculty of Medicine, ULg

Course Director:
Natzi SAKALIHASAN
Liège, Belgium

Co-Director:
Jean-Olivier DEGRAFNE
Liège, Belgium

Scientific Committee:
Matt BOWN
Cardiff, United Kingdom
Audrey COURTOIS
Liège, Belgium
Alessandro DELLA CORTE
Napoli, Italy
John ELEFTRIADES
New Haven, USA
Rebecka HULTGREEN
Stockholm, Sweden
Gregory JONES
Dunedin, New Zealand
Nicos LABROPOULOS
Stony Brook, USA
Frank LEDERLE
Minneapolis, USA
Víctor LEGRAND
Liège, Belgium
Christoph NIENABER
London, United Kingdom
Florence PINET
Lille, France
Marc RADERMECKER
Liège, Belgium

Juliette ALBUISSON, Paris, France
Eric ALLAIRE, Creteil, France
Valery ARAKELYAN, Moscow, Russia
George ASIMAKOPOULOS, Bristol, United Kingdom
Parla ASTARCI, Bruxelles, Belgium
Domenico BACCHELLERI, Milan, Italy
Jean-Pierre BEQUEMIN, Champaign, France
Yadav BHATTA, Kathmandu, Nepal
Colin BICKNELL, London, United Kingdom
Malenka BISSEL, Oxford, United Kingdom
Simon BODY, Boston, USA
Jan BRUNKWALL, Köln, Germany
Rachel CLOUGH, London, United Kingdom
Ronald DALMAN, Stanford, USA
Lazar B. DAVIDOVIC, Suruc, Serbia
Julie DE BACKER, Gent, Belgium
Frédéric COLLART, Marseille, France
Jean-Paul DE VRIES, Nieuwegein, The Netherlands
Barry DOYLE, Perth Australia
Helena DULGHERU, Ljeb, Belgium
Rodolphe DUREUX, Liège, Belgium
Hans-Henning ECKSTEIN, Munich, Germany
Sean ENGLISH, St Leu, USA
Per ERIKSSON, Stockholm, Sweden
Daniel FINK, Jerusalem, Israel
Peter FRAMBACH, Luxembourg
Julien GAÉ, Harfleid, United Kingdom
Christian GASSER, Stockholm, Sweden
Athanasiou GIANNOUKAS, Larissa, Greece
Evdokia GIRDAS, Bad Berka, Germany
Jonathan GOLLEDGE, Townsville, Australia
David GUZZARDI, Calgary, Canada
Grégory HANS, Liège, Belgium
Dominic HOWARD, Oxford, United Kingdom
Arne S JUPMA, Rotterdam, the Netherlands
Heinz JAKOB, Essen, Germany
Fabien KOSKAS, Paris, France
Dung LE HUU, Ho Chi Minh, Vietnam
Jan LINDEMAN, Leiden, The Netherlands
Jes LINDHOLT, Viborg, Denmark
Bart LOEYS, Antwerp, Belgium
Lars MAGIEREFESSEL, Stockholm, Sweden
Danielle MAJORD, Rotterdam, The Netherlands
Mitiotis MATSAGKAS, Larissa, Greece
Bart MEURIS, Leuven, Belgium
Jean-Baptiste MICHEL, Paris, France
Rita MILEWSKI, Philadelphia, USA
Thomas MODINE, Lille, France
Firas MUSSA, New York, USA
Paul NORMAN, Fremantle, Australia
Betty NUGENS, Liège, Belgium
Domenico PALOMBO, Genova, Italy
Luc PIERARD, Liège, Belgium
Janet POWELL, London, United Kingdom
Cesare QUARTO, London, United Kingdom
Morgan SALMON, Charlotteville, USA
Thanos SARATZIS, Leicester, United Kingdom
Toru SUZUKI, Leicester, United Kingdom
Apostolos TASSIOPOULOS, Gleno brok, USA
Vincent TCHAN SATO, Liège, Belgium
Gilbert R. UPCHURCH, Charlotteville, USA
Rao Srinivasava VALLABHANENI, Liverpool, United Kingdom
Isabelle VAN HERZEEL, Gent, Belgium
Isabelle VAN HERZEELE, Gent, Belgium
Eric VERHOEVEN, Nümburg, Germany
Emiliano VOTTA, Milan, Italy
Pascal VRANCKX, Hasselt, Belgium
Anders WANNHANEN, Uppsala, Sweden
James YEH, London, United Kingdom
Koichi YOSHIMURA, Yamaguchi, Japan

ENGLISH, USA
## Synoptic

### Thursday September 15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Genetics of aortic diseases</td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30</td>
<td>Epidemiology and treatment of AAA</td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch break</td>
</tr>
<tr>
<td>13.30</td>
<td>New advances in physiopathology of aortic diseases</td>
</tr>
<tr>
<td>15.00</td>
<td>Generalities on medical treatment of AAA</td>
</tr>
<tr>
<td>16.45</td>
<td>Coffee break</td>
</tr>
<tr>
<td>17.15</td>
<td>Causes and management of ruptured AAA</td>
</tr>
<tr>
<td>19.05</td>
<td>End of the sessions</td>
</tr>
</tbody>
</table>

### Friday September 16

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Aortic dissection</td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30</td>
<td>Challenging cases of aortic dissection</td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch break</td>
</tr>
<tr>
<td>13.30</td>
<td>TEVAR for TAA</td>
</tr>
<tr>
<td>15.00</td>
<td>Potpourri related with aortic diseases</td>
</tr>
<tr>
<td>16.45</td>
<td>Coffee break</td>
</tr>
<tr>
<td>17.10</td>
<td>Generalities on EVAR</td>
</tr>
<tr>
<td>19.15</td>
<td>End of the sessions</td>
</tr>
</tbody>
</table>

### Saturday September 17

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Risk stratification in BAV aortopathy: new concepts</td>
</tr>
<tr>
<td>09.45</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.15</td>
<td>Ascending aorta</td>
</tr>
<tr>
<td>11.30</td>
<td>Industry sponsored symposium</td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch break</td>
</tr>
<tr>
<td>13.30</td>
<td>Aortic arch</td>
</tr>
<tr>
<td>15.00</td>
<td>Aortic valves</td>
</tr>
<tr>
<td>17.00</td>
<td>Awards ceremony</td>
</tr>
<tr>
<td>17.30</td>
<td>Adjournment</td>
</tr>
</tbody>
</table>

---

20.00 **IMAD Official dinner - Thursday**

Palais Provincial

All delegates are welcome to register with one guest. Seated dinner.

Participation fee: 55 € per person.
Thursday September 15

08.00 Welcome address, Natzi Sakalihasan
Distinguished lecture, Frank Lederle

I Genetics of aortic diseases
Greg Jones, Matthew Bown

08.30 Extra-aortic cardiovascular features in Marfan syndrome - Relevance and management, Julie De Backer
08.38 Whole blood DNA methylation analysis in AAA; an epigenome-wide association study, Greg Jones
08.46 Combining Mendelian genetics and genetic epidemiology for AAA, Juliette Albuissou
08.54 New insights on genetic aspect of aortic disease, John Elefteriades
09.02 Does sex matter in aortic aneurysm and dissection? Bart Loeys
09.10 Genetic risk profile: insights from family based AAA NGS analysis, Danielle Majoor, Arne S. Ijpma
09.26 Discussion

Short communications from selected papers
09.35 High heritability of abdominal aortic aneurysms – a population-based twin-study, Trine Maria Mejnert Joergensen
09.40 Global and gene specific DNA methylation is associated with Abdominal Aortic Aneurysms, Bradley Toghill
09.45 End-stage human aneurysm disease in different arterial positions is similar – aneurysm induction in mouse models however not, Albert Busch
09.50 Phenotypic switching of SMCs is a potential therapeutic target in popliteal aneurysms, Albert Busch
09.55 Resveratrol inhibits aortic root dilatation in the Fbn1C1039G/+ Marfan mouse model, Vivian de Waard

10.00 Coffee break

I Epidemiology and treatment of AAA
Frank Lederle, Anders Wanhainen

10.30 Findings from the Swedish AAA screening program, Anders Wanhainen
10.40 Is risk-factor targeted AAA screening the future? Data from the Oxford Vascular Study, Dominic Howard
10.50 Morphology of ruptured vs unruptured AAA, Janet T. Powell
11.00 AAA rupture in Stockholm, Rebecka Hultgren
11.10 Australian trials to identify treatments to slow AAA growth, Jonathan Golledge
11.20 AAA measurement and enlargement, Frank Lederle
11.30 CT-overestimation of AAA size severely impacts the cost-effectiveness of AAA repair, Jan Lindeman
11.40 Discussion

Short communications from selected papers
12.10 Immunopathology in patients with AAA, Miroslav Prucha
12.15 How does it feel to have an abdominal aortic aneurysm – a patient-centered view, Stephanie Tomee
12.20 Meta-analysis of the current prevalence of screen-detected abdominal aortic aneurysm in women, Pinar Ulug
12.25 Diameter growth rate and future indication for surgery can be predicted with finite element analysis and semi-automatic diameter measurements in small abdominal aortic aneurysms, Moritz Lindquist Liljeqvist
12.30 Lunch break

I New advances in physiopathology of aortic diseases
Audrey Courtois, Florence Pinet

13.30 Inward neo-angiogenesis in aortic diseases, Jean-Baptiste Michel
13.38 NETosis is associated with abdominal aortic aneurysm rupture, Sean English
13.46 The translational story of the relationship between reversible pulmonary obstructive disease and AAA, Jes Lindholt
13.54 Non-coding RNA and aneurysm, clinical implications: form experimental animal models to therapeutics approaches, Lars Maegdefessel
14.02 Cell-specific expression of non coding RNA in human AAA: new approach to find biomarkers, Florence Pinet
14.10 Circulating miRNA associated with unstable abdominal aortic aneurysm PET positive, Audrey Courtois
14.18 Circulating vascular basement fragments are associated with the diameter of abdominal aorta, Anders Wanhainen
14.26 Discussion

Short communications from selected papers
14.50 Transdifferentiation of human dermal fibroblasts to smooth muscle like cells: a novel method to study the effect of MYH11 and ACTA2 variants in the aortic aneurysm wall, Natalija Bogunovic
14.55 Live human arterial tissue slices for bench top research on pathophysiology of aortic aneurysms; up to 90 days ex vivo preservation, Jorn Meekel
Thursday September 15

Generalities on medical treatment of AAA
Gilbert R. Upchurch, Paul Norman

15.10 Where and why does thrombus develop in aortic disease, Barry Doyle
15.18 Focal adhesion Kinase is a novel target for pharmacotherapy of abdominal aortic aneurysm, Koichi Yochimura
15.26 Inhibition of aneurysmal progression by local PGG infusion in experimental porcine AAA, Jes Lindholt
15.34 Telmisartan in the management of abdominal aortic aneurysm (TEDY): the study protocol for a randomized controlled trial, Jonathan Golledge
15.42 What is the role of the KLF4 during the development of abdominal aortic aneurysm, Morgan Salmon
15.50 The effect of metformin on AAA, Ronald Dalman
15.58 What do we know about AAA and diabetes and does it matter? Paul Norman

Keynote lecture. Medical treatment of the AAA in human. Fiction or reality?
Gilbert R. Upchurch

16.14 Discussion

Short communications from selected papers

16.30 • Inhibition of pathological vascular smooth muscle cell remodelling as a treatment strategy for abdominal aortic aneurysm, Marc Bailey
16.35 • Canonical TGFβ-signaling is triggered by inflammation in human non-syndromic aneurysm disease, but is not reflected by inducible AAA mouse models, Albert Busch
16.40 • Phenotyping of transgenic pigs to determine the suitability of xenografts in the treatment of aortic diseases, Ewa Strauss

16.45 Coffee break

Causes and management of ruptured AAA
Rebecka Hultgren, Ronald Dalman

17.15 The biology of AAA progression and rupture: beyond MMPs and inflammation, Jan Lindeman
17.23 Imaging alternatives in order to prevent rupture [volume vs diameter], Christian Gasser
17.31 Is the risk different for female or male FDRs to AAA patients? Rebecka Hultgren
17.39 Emergency EVAR – the new standard for almost every patient with a ruptured AAA (technique and own clinical data over 10 years, literature review), Hans-Henning Eckstein
17.47 Open repair of RAAA is always possible - is it always better? Lazar Davidovic
17.55 Prolonged or renewed ICU stay after AAA-repair - a "crash investigation", Anders Wanhainen

18.03 TAVI, MAVI, TEVAR, EVAR - The end of standard cardiovascular surgery? Perspectives of a cardiac surgeon, Daniel Fink
18.11 Staged hybrid repair of extensive TAAA, Gilbert R. Upchurch
18.19 Keynote lecture. Lessons learned from IMPROVE trial, Janet T. Powell
18.27 Questions to experts & panel discussion

Short communications from selected papers

18.40 • Management of visceral artery aneurysms: a 20-year single centre experience, Gianfranco Filippone
18.45 • Aortic size index could improve surveillance of women and men with AAA, Rebecka Hultgren
18.50 • How common is the classic triad of symptoms in patients with ruptured AAA? Rebecka Hultgren
18.55 • Survival disparity following AAA repair highlights inequality in socioeconomic status, Manar Khashram
19.00 • Patient reported quality and functional life after AAA repair, Manar Khashram
19.05 End of the sessions

20.00 Official dinner (upon registration)
Friday September 16

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Diagnostic algorithm for acute aortic dissection – imaging and biomarkers, Toru Suzuki</td>
</tr>
<tr>
<td>08.40</td>
<td>Therapeutic pathways in acute aortic dissection, Cesare Quarto</td>
</tr>
<tr>
<td>08.50</td>
<td>Can we predict aortic size PRIOR to dissection? Yes! John Elefteriades</td>
</tr>
<tr>
<td>09.10</td>
<td>Computational modelling of type B aortic dissection: does it help manage patients? Barry Doyle</td>
</tr>
<tr>
<td>09.20</td>
<td>Initial experience in dissection of aorta in Nepal, Yadav Bhatta</td>
</tr>
<tr>
<td>09.30</td>
<td>Keynote lecture. Christoph Nienaber</td>
</tr>
<tr>
<td>09.40</td>
<td>Discussion</td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30</td>
<td>Challenging cases of aortic dissection</td>
</tr>
<tr>
<td>10.40</td>
<td>Aortic dissection – the great masquerader, James Yeh</td>
</tr>
<tr>
<td>10.50</td>
<td>Proximal aortic dissection – the role of the frozen elephant, Heinz Jakob</td>
</tr>
<tr>
<td>11.00</td>
<td>Staged repair of complex aortic dissection – safer or superfluous? Jullien Gaer</td>
</tr>
<tr>
<td>11.10</td>
<td>Retrograde aortic dissection after TEVAR: incidence, risk factors, precautions and treatment, Firas Mussa</td>
</tr>
<tr>
<td>11.20</td>
<td>Positive family history of aortic dissection dramatically increases dissection risk in family members, John Elefteriades</td>
</tr>
<tr>
<td>11.30</td>
<td>Clinical outcomes of TBADs in patients with connective tissue diseases (Marfan, Loeys-Dietz, etc.) are worse than in those without, Firas Mussa</td>
</tr>
<tr>
<td>11.40</td>
<td>Case presentation and discussion: severe lower extremity malperfusion in a patient with acute type A dissection, what is the priority? Vincent Tchana-Sato</td>
</tr>
<tr>
<td>11.50</td>
<td>Type B aortic dissection in the patient with MYLK variants. What is the best solution: TEVAR or open repair? Vincent Tchana-Sato</td>
</tr>
<tr>
<td>12.00</td>
<td>Questions to experts and panel discussion</td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch break</td>
</tr>
<tr>
<td>13.30</td>
<td>Open surgical conversion after TEVAR: incidence and treatment options, Domenico Baccelli</td>
</tr>
<tr>
<td>13.39</td>
<td>Spinal cord ischemia in TAAA branched grafting, Eric Verhoeven</td>
</tr>
<tr>
<td>13.48</td>
<td>CSF drainage in TEVAR: anesthetic considerations, Gregory Hans</td>
</tr>
<tr>
<td>13.57</td>
<td>Neuromonitoring using motor and somatosensory evoked potentials in aortic surgery, John Elefteriades</td>
</tr>
<tr>
<td>14.06</td>
<td>Is there an increased risk to more complex fenestrated EVAR? Eric Verhoeven</td>
</tr>
<tr>
<td>14.15</td>
<td>Fenestrated and branched grafts: lessons after four years of the Windows trial, Jean-Pierre Becquemin</td>
</tr>
<tr>
<td>14.24</td>
<td>Consensus exercise on management of thoracic and thoracoabdominal aortic aneurysms in the United Kingdom, Srinivasa R. Vallabhaneni</td>
</tr>
<tr>
<td>14.33</td>
<td>Type B dissection: update on indications and results using a pragmatic policy, Fabien Koskas</td>
</tr>
<tr>
<td>14.42</td>
<td>Ask to experts and panel discussion</td>
</tr>
<tr>
<td>15.00</td>
<td>Potpourri related with aortic diseases</td>
</tr>
<tr>
<td>15.08</td>
<td>Management of graft infection after EVAR-TEVAR. Can PET-CT predict the outcome of prosthetic graft infections? Natzi Sakalihasan</td>
</tr>
<tr>
<td>15.16</td>
<td>Extra anatomic bypass for congenital and acquired disorders of the thoracic aorta: indications, technique, results, Valery Arakelyan</td>
</tr>
<tr>
<td>15.47</td>
<td>Keynote lecture. Medical errors during endovascular treatment for aortic diseases. How can we avoid them? Colin D. Bicknell</td>
</tr>
<tr>
<td>15.57</td>
<td>Discussion</td>
</tr>
<tr>
<td>16.20</td>
<td>Incidence, treatment and long-term clinical outcome in patients with aortic graft infections, Jennifer Pettersson</td>
</tr>
<tr>
<td>16.25</td>
<td>Sex differences in outcomes after AAA repair in the United Kingdom, Matthew Bown</td>
</tr>
<tr>
<td>16.30</td>
<td>Exploitation of a fenestrated abdominal endograft with autologous venous reconstruction for infection, Catherine Terry</td>
</tr>
<tr>
<td>16.40</td>
<td>Coffee break</td>
</tr>
<tr>
<td>17.00</td>
<td>Generalities on EVAR</td>
</tr>
<tr>
<td>17.08</td>
<td>Radiation protection for patient and staff during routine EVAR and TEVAR procedures, Miltiadis Matsagkas</td>
</tr>
<tr>
<td>17.16</td>
<td>Management of graft infection after EVAR-TEVAR. Can PET-CT predict the outcome of prosthetic graft infections? Natzi Sakalihasan</td>
</tr>
<tr>
<td>17.32</td>
<td>Extra anatomic bypass for congenital and acquired disorders of the thoracic aorta: indications, technique, results, Valery Arakelyan</td>
</tr>
<tr>
<td>17.47</td>
<td>Keynote lecture. Medical errors during endovascular treatment for aortic diseases. How can we avoid them? Colin D. Bicknell</td>
</tr>
<tr>
<td>17.57</td>
<td>Discussion</td>
</tr>
<tr>
<td>18.20</td>
<td>Short communications from selected papers</td>
</tr>
<tr>
<td>18.25</td>
<td>Incidence, treatment and long-term clinical outcome in patients with aortic graft infections, Jennifer Pettersson</td>
</tr>
<tr>
<td>18.30</td>
<td>Sex differences in outcomes after AAA repair in the United Kingdom, Matthew Bown</td>
</tr>
<tr>
<td>18.40</td>
<td>Exploitation of a fenestrated abdominal endograft with autologous venous reconstruction for infection, Catherine Terry</td>
</tr>
<tr>
<td>18.40</td>
<td>Coffee break</td>
</tr>
<tr>
<td>19.00</td>
<td>Generalities on EVAR</td>
</tr>
<tr>
<td>19.08</td>
<td>Radiation protection for patient and staff during routine EVAR and TEVAR procedures, Miltiadis Matsagkas</td>
</tr>
<tr>
<td>19.16</td>
<td>Management of graft infection after EVAR-TEVAR. Can PET-CT predict the outcome of prosthetic graft infections? Natzi Sakalihasan</td>
</tr>
<tr>
<td>19.32</td>
<td>Extra anatomic bypass for congenital and acquired disorders of the thoracic aorta: indications, technique, results, Valery Arakelyan</td>
</tr>
<tr>
<td>19.47</td>
<td>Keynote lecture. Medical errors during endovascular treatment for aortic diseases. How can we avoid them? Colin D. Bicknell</td>
</tr>
<tr>
<td>19.57</td>
<td>Discussion</td>
</tr>
</tbody>
</table>
Friday September 16

17.10 Impact of geometry and respiratory-induced deformation during snorkel/chimney and fenestrated endografts for complex abdominal aortic aneurysms, Ronald Dalman

17.20 Flow characteristics of Type II endoleaks. Does it matter? Nicos Labropoulos

17.30 Invisible endoleak after stent graft: a ghost or a myth? Eric Allaire

17.40 Apposition of the endograft post-EVAR. Improved technique to calculate and its importance to predict failure, Jean-Paul de Vries

17.50 Patients’ compliance with post-EVAR follow-up and its impact on the outcome, Athanasios Giannoukas

18.00 Early and long-term outcomes after open or endovascular repair for abdominal aortic aneurysms in high-risk patients, Domenico Palombo

18.10 Renal function is the main predictor of acute kidney injury after endovascular abdominal aortic aneurysm repair, Thanos Saratzis

18.20 Is there a role for use of endoanchors in EVAR or TEVAR procedures? Apostolos Tassiopoulos

18.30 Profile of secondary interventions after EVAR in current practice: how are they triggered and what are the implications for surveillance? Srinivasa R. Vallabhaneni

18.50 Case presentation, Isabelle Van Herzeele

19.00 Questions to experts and panel discussion

19.15 End of the sessions
Saturday September 17

- **Risk stratification in BAV aortopathy: new concepts**
  - Allessandro Della Corte, Simon Body
  - 08.30 Genotype-based risk stratification of BAV disease: dream or reality? Simon Body
  - 08.40 Implementing phenotype-based risk stratification of BAV aortopathy in surgical practice, Evaldas Girdauskas
  - 08.50 Structural finite element modelling of the bicuspid root to understand disease progression, Emiliano Votta
  - 09.00 Functional imaging of the BAV aorta to predict aortopathy progression, Malenka Bissell
  - 09.10 Identifying circulating biomarkers of BAV aortopathy risk, Allessandro Della Corte
  - 09.30 Questions to experts and discussion

- **Short communications from selected papers**
  - 09.35 Aortopathy in patients with a bicuspid aortic valve: a process beyond normal cardiovascular ageing, Nimrat Grewal
  - 09.40 The role of hemodynamics and shear stress on the ascending aortic wall in patients with a bicuspid aortic valve, Nimrat Grewal

- **Coffee break**

- **Ascending aorta**
  - John Elefteriades, Jean-Olivier Defraigne
  - 10.15 The pathology of thoracic aortic aneurysm, Per Eriksson
  - 10.25 Twenty-five year outcome of composite graft aortic root replacement: near “curative” impact on aortic root disease, John Elefteriades
  - 10.35 Is there really research-based evidence for a guideline dimension for ascending aortic aneurysm repair? Simon Body
  - 10.45 How to classify the dilatations of the ascending aorta? Allessandro Della Corte
  - 10.55 Modeling of predissection aortic size in acute type A dissection: more than 90% fail to meet the guidelines for elective ascending replacement, Rita K Milewski
  - 11.05 Management of aorto-ventricular tunnels: a rare cause (disregarded) of the heart failure in occidental countries. Single center experiences in HCMC, Vietnam, Dung Le Huu, Natzi Sakalihasan
  - 11.15 Questions to experts and discussion

- **Industry sponsored symposium (See page 17)**

- **Lunch break**

- **Aortic arch**
  - Firas Mussa, Jan Brunkwall
  - 13.30 Supraaortic debranching and TEVAR for arch aneurysms – is it a valid alternative for open surgery? (Single center series on > 50 pts), Hans-Henning Eckstein
  - 13.40 Branched endograft vs. chimney techniques for treating complex arch lesions. Which is best, when and why, Firas Mussa
  - 13.50 Update on total arch endovascular repair, Rachel Clough
  - 14.00 Various cardiac access routes to treat ascending aortic and arch lesions: advantages and limitations, Firas Mussa
  - 14.10 Does the bovine arch have any influence on the outcome of arch stentgrafting in dissections? Jan Brunkwall
  - 14.20 Distal aortic reintervention after surgery for acute DeBakey type I or II aortic dissection: open vs. endovascular repair, Rita K. Milewski

- **Keynote lecture. Hybrid stent-grafts: factotum of open surgery of the aortic arch?** Fabien Koskas

- **Discussion**

- **Short communications from selected papers**
  - 14.50 Deep hypothermia with retrograde cerebral perfusion – as method of brain protections in ascending aorta and arch aneurysms surgery, Vitalii Kravchenko
  - 14.55 Aneurysm at the site of repair of coarctation of aorta: frequency, methods of treatment, results, Vitalii Kravchenko

- **Aortic valves**
  - Marc Radermecker, Victor Legrand
  - 15.00 TAVI indications, Luc Piérard
  - 15.10 New imaging modalities for assessment of TAVI procedure and results, Helena Gulheru
  - 15.20 Critical analysis of recent registries and randomized trials, Victor Legrand
  - 15.30 Choice of the best transcatheter site for implantation, Marc Radermecker
  - 15.40 Off label indications: where are we? Thomas Modine
  - 15.50 Antithrombotic treatment: DAPT or OAC? Pascal Vranckx
  - 16.00 Rapid deployment aortic bioprosthesis in patients with small aortic annulus, Frédéric Collart
  - 16.10 Valve fair: review of actual and future devices, Peter Frambach
  - 16.20 New insight of percutaneous native aortic valve resection prior to TAVI, Parla Astarci
  - 16.30 Sutureless aortic valve replacement: worldwide experience, Bart Meuris
  - 16.40 Case presentation and discussion: valve thrombosis after transcatheter aortic valve implantation, Rodolphe Durieux

- **Discussion**

- **Closing remarks & Awards ceremony**

- **Adjournment**
**Adventitial adipogenic degeneration: an unidentified contributor to aortic wall weakening in the abdominal aortic aneurysm**

**PET-TC utility to assess the abdominal aortic aneurysm growth and its relationship with changes in energetic metabolism**
Angel Galindo, Guillermo Moñux, Javier Modrego, Roberto Delgado, Manuela Maria Hernandez, Antonio Jose Lopez-Farre, Francisco Javier Serrano

**Evidence of intimal tear in aortic intramural hematoma**
Gianfranco Filippone, Rosalba Franchino, Alessandro Ricasoli, Vincenzo Argano

**The application of metabolic profiling to aneurysm research**
Michele Greco, Mahim Qureshi, Vorkas Panagiotis, Elaine Holmes, Alun H Davies

**Preoperative fibrinogen levels and early outcome following endovascular repair of ruptured abdominal aortic aneurysms**
Christos Karkos, Aristotelis Ilantis, Christina Papadimitriou, Ioannis Pliatsios, Dimitrios Pelekas, Maria-Afroditi Mitka, Konstantinos Papazoglou

**Inflammation as a predictor of abdominal aortic aneurysm growth and rupture: a systematic review of imaging biomarkers**
Hamid Jalalzadeh, Reza Indrakusuma, R.N. Planken, D.A. Legemate, M.J.W. Koelemay, Ron Balm

**The association of mmp9 and mmp13 functional genetic polymorphisms and abdominal aortic aneurysm in a Greek population**
Georgios Makrygiannis, Evanthia Mourmoura, Konstantinos Spanos, Nikolaos Roussas, Aspasia Tsezou, Athanasios Giannoukas

**Can aortic root replacement with a graft affect cardiac function in patients with marfan syndrome?**
Laura Muino Mosquera, Katrien François, Thierry Bové, Daniel De Wolf, Julie De Backer

**Cholesterol precursors in patients with AAA**
Miroslav Prucha, Petr Sedivy, Petr Stadler

**Gene expression signature in patients with abdominal aortic aneurysm**
Miroslav Prucha, Petr Sedivy, Petr Stadler, Pavel Zdrahal

**The natural history of a large aorta is greater cardiovascular risk**
Matthew Bown, David Sidloff, Athanasios Saratzis

**Overview about the value of functional imaging in the management of aortitis**
Bruls Samuel, Courtois Audrey, Nusgens Betty, Delraigne Jean-Olivier, Delvenne Philippe, Hustinx Roland, Moutschen Michel, Sakalihasan Natzi

---

**Jury:** Firas Mussa, Hans-Henning Eckstein, Betty Nusgens

**Posters**

Presented during the morning and lunch breaks

Saturday at 9.45 and 12.30

---

**Industry sponsored symposium**

**Perceval Focus Group Belgium**

Prof. M.A. Radermecker, Prof. B. Meuris, Prof. B. Paelinck

The role of Echo in PRE-Operative, PERI-Operative and POST-Operative setting when using Perceval, Grégory Hans

Technical considerations when sizing for a Perceval implantation In-vitro and In-vivo testing, Parla Astarci

Treatment indications: recommendations and new options, Jean-Marc Marnette
General information

Meeting venue
Crowne Plaza Hotel
9-11, rue du Mont St Martin, Liège, Belgium
www.crowneplazaliege.be

HOTELS
1. Crowne Plaza - Congress venue
   9-11, rue du Mont St Martin
   www.crowneplazaliege.be
2. Pentahotel Liège**** (5 min. walk)
   100, bd de la Sauvenière
   www.pentahotels.com
3. Ibis Liège Centre Opéra*** (5 min. walk)
   41, place de la république Française
   www.ibis.com

REGISTRATION & INFORMATION DESK
Thursday ......................... 07.30 - 19.00
Friday ......................... 08.00 - 19.30
Saturday ......................... 08.00 - 17.30

EXHIBITION HOURS
Thursday ......................... 09.30 - 19.00
Friday ......................... 09.00 - 19.30
Saturday ......................... 09.00 - 14.00

EXHIBITORS

<table>
<thead>
<tr>
<th>BOOTH</th>
<th>INDUSTRIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>MEDTRONIC</td>
</tr>
<tr>
<td>2</td>
<td>COOK MEDICAL</td>
</tr>
<tr>
<td>3</td>
<td>VITALITEC</td>
</tr>
<tr>
<td>4</td>
<td>BARD</td>
</tr>
<tr>
<td>5</td>
<td>JOHNSON&amp;JOHNSON MEDICAL</td>
</tr>
<tr>
<td>8</td>
<td>EUROSETS</td>
</tr>
<tr>
<td>11</td>
<td>ST JUDE MEDICAL</td>
</tr>
<tr>
<td>12</td>
<td>HOSPITHERA</td>
</tr>
<tr>
<td>13</td>
<td>MAQUET</td>
</tr>
<tr>
<td>14</td>
<td>LIVANOVA</td>
</tr>
<tr>
<td>16</td>
<td>EDWARDS</td>
</tr>
</tbody>
</table>
**EVENT COORDINATORS’ CONTACTS**

Christine Arzouyan  
General organization  
Mobile: +33 613 96 08 70  
carzouyan@divine-id.com

Cyrielle Launoy  
Faculty  
claunoy@divine-id.com

Vérane Bergeron Moreau  
Executive manager  
Mobile: +33 621 78 87 16  
vbergeron@divine-id.com

**LOCAL CONTACT**

Geneviève Péters  
Scientific program  
CHU Liège • Belgium  
Tel.: +32 4 366 43 49  
genevieve.peters@chu.ulg.ac.be

**ORGANIZATION**

divine [id] agency  
17, rue Venture • 13001 Marseille • France  
Tel.: +33 491 57 19 60  
Fax: +33 491 57 19 61  
info@divine-id.com  
www.divine-id.com